Insmed (INSM) Misses Q2 EPS by 22c

Insmed (NASDAQ: INSM) reported Q2 EPS of ($1.07), $0.22 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $45.4 million versus the consensus estimate of $43.72 million.

"Insmed made meaningful progress in the second quarter of 2021, with important achievements across our four pillars-ARIKAYCE, brensocatib, TPIP, and translational medicine," commented Will Lewis, Chair and Chief Executive Officer of Insmed. "With the launch of ARIKAYCE just last month in Japan, the largest market for refractory MAC lung disease that we are pursuing, we\'re thrilled that our lead product is now available in three major territories. We continue to enroll patients in both the Phase 3 ASPEN study of brensocatib in patients with bronchiectasis and the ARIKAYCE frontline clinical trial program in patients with NTM lung disease in line with expectations, and we are advancing TPIP to Phase 2 development in both PAH and PH-ILD. As we carry forward learnings from the past year and a half in navigating the pandemic, we have great confidence in our ability to execute on our commercial and clinical activities around the world."

For earnings history and earnings-related data on Insmed (INSM) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
• Currenc Group suspends Indonesian WalletKu unit operations